Allergan, Pfizer Call Off Proposed $160B Merger
Allergan and Pfizer are calling off a record $160 billion merger after the Treasury issued new rules to make “tax inversions” less lucrative.
The aggressive changes to U.S. tax laws announced this week helped to kill the deal. The merger would have moved Pfizer’s address — but not its operations or headquarters — to Ireland where it would’ve paid far less in corporate taxes.
Pfizer Inc., based in New York, has agreed to pay Allergan PLC $150 million for reimbursement of expenses.
To Read The Full Story
Are you already a subscriber?
Click "Sign In" to log in!
Become a Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Become a Print + Web Subscriber
Click “Subscribe” below to begin the process of becoming a new subscriber.
Renew Print + Web Subscription
Click “Renew Subscription” below to begin the process of renewing your subscription.
